Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Clin Chim Acta. 2020 Nov;510:475-482. doi: 10.1016/j.cca.2020.08.019. Epub 2020 Aug 14.
Since its first description, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), formerly known as 2019-nCoV, has attracted tremendous attention in a short period of time as the death toll and number of confirmed cases grows unceasingly.
To provide a better understanding of the importance of abnormal laboratory findings in COVID-19 diagnosis and prognosis, we searched the Scopus, PubMed, and Web of Science medical databases and selected 19 articles (totaling 2988 patients, 484 of whom [16.1%] had severe disease) that reported panels of laboratory examinations in patients with COVID-19.
Although in vitro diagnostics, primarily using PCR- and ELISA-based methods, efficiently contribute to the etiological identification of SARS-CoV-2 infection, we suggest that laboratory medicine may also be of significant assistance when differentiating between severe and non-severe COVID-19.
When we wrote this article, our ability to provide a definitive conclusion may have been adversely affected by some limitations, such as the low sample size, differently applied methods, dissimilar reference ranges, non-synchronized representations of results, and variety of the patients' panels. Despite the limitations, the analysis of the current scientific literature demonstrates the value of laboratory parameters as simple, rapid, and cost-effective biomarkers in COVID-19 patients.
自首次描述以来,严重急性呼吸综合征冠状病毒 2(SARS-CoV-2),以前称为 2019-nCoV,在短时间内引起了极大关注,因为死亡人数和确诊病例不断增加。
为了更好地了解异常实验室发现对 COVID-19 诊断和预后的重要性,我们搜索了 Scopus、PubMed 和 Web of Science 医学数据库,并选择了 19 篇报告 COVID-19 患者实验室检查组合的文章(共 2988 例患者,其中 484 例[16.1%]为重症)。
尽管体外诊断主要使用基于 PCR 和 ELISA 的方法,有效地有助于 SARS-CoV-2 感染的病因鉴定,但我们认为实验室医学在区分重症和非重症 COVID-19 方面也可能有很大帮助。
当我们撰写这篇文章时,由于一些限制因素,如样本量小、应用方法不同、参考范围不同、结果的表示不统一以及患者检测组合的多样性,我们可能无法提供明确的结论。尽管存在这些局限性,但对当前科学文献的分析表明,实验室参数作为 COVID-19 患者的简单、快速和具有成本效益的生物标志物具有价值。